Skip to main content
DFTX logo

DFTX · Definium Therapeutics, Inc. · Holdings

Track DFTX — free
$29.48 +0.36 (+1.24%) Play latest call Q3 2026 earnings call transcript
Market Cap
$4.04B
Shares
136.90M
Volume · Nov 19 2.86M Avg daily vol (3M) 1.98M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 361
Total Value: $4,485,750,186
Total Shares: 117,859,969
Showing 1–100 of 376 holdings by value · page 1 of 4

Institutional Ownership Trend

20 quarters

Holder Concentration

Share of 13F common-share value, across 361 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
10.0%
Dec 2023 → Sep 2026 · range 9.8% – 19.5%
+0.2 pts
Top 5
36.8%
Dec 2023 → Sep 2026 · range 31.6% – 59.8%
+5.2 pts
Top 10
55.3%
Dec 2023 → Sep 2026 · range 47.6% – 80.7%
+7.1 pts
HHI
393
Dec 2023 → Sep 2026 · range 326 – 976
Broadly held+67

Who Holds DFTX

Last 8 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 354 filers, like-for-like change +1.4%; actively managed books -0.3%; index-like books +6.5%.

Holder type Share Filers Change
Registered adviser 42.4% 192 -10.9%
Exempt adviser 1.2% 6 -42.5%
Adviser 18.7% 13 +11.1%
Bank 7.1% 18 +31.6%
Insurer 0.0% 3 -30.6%
Broker-dealer 0.1% 1 -43.9%
Benefit plan 0.2% 6 +14.9%
Non-US 0.4% 8 -18.7%
Holding company 24.0% 11 +27.9%
Unknown 5.9% 96 -11.1%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 5 holders with no observed 2026-06-30 13F and 7 holders with no observed 2026-09-30 13F.

Conviction and Crowding

354 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
10
2.82% of filers hold it in their top 10
Jun 30, 2026: 13
Holders above 5%
3
median weight 0.005%
Jun 30, 2026: 4
Crowding
30.6%
of shares outstanding, 81st percentile
Private-fund advisers
30.0%
of shares outstanding
Institutional ownership
87.7%
90.8% of the estimated free float
Top 10 holders
55.3%
of 13F shares, Herfindahl 0.039
Active holders
-0.3%
like-for-like share change of active filers
5% stakes on record
5
0 13D, 5 13G (5 institutional, 0 passive, 0 exempt)
How long holders have held it value-weighted 2.9 quarters
Under 1 year 88.7% 1 to 3 years 11.3% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net sellers of $54,407,195 (23 buying, 34 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$23.86
estimated per share
Jun 30, 2026: $19.76
Quarter-end price
$38.06
implied by 13F values
Estimated gain or loss
+59.5%
price against the estimated cost
Estimated at a loss
5.29%
of costed 13F value

Estimated cost covers 90.0% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies DFTX's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 SYRE Spyre Therapeutics, Inc. 17
2 DNTH Dianthus Therapeutics, Inc. 16
3 COGT Cogent Biosciences, Inc. 19
4 TNGX Tango Therapeutics, Inc. 17
5 ELVN Enliven Therapeutics, Inc. 15
6 CMPS COMPASS Pathways plc 15
7 ERAS Erasca, Inc. 14
8 ABVX Abivax S.A. 21
9 KYMR Kymera Therapeutics, Inc. 14
10 CLDX Celldex Therapeutics, Inc. 13

Shareholder Targets

13F filers that own its peers but not DFTX, quarter ended Sep 30, 2026

Found through its holder-overlap peers: SYRE, DNTH, COGT, TNGX, ELVN, CMPS, ERAS, ABVX, KYMR, CLDX, AXSM, IMVT, ORKA, NKTR, AMLX, PHVS, PRAX, EWTX, PALI, FTH. 711 filers in all.

# Filer In peers
1 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $1,954,118,705 9 held
2 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $1,925,184,783 8 held
3 RTW INVESTMENTS, LP Registered adviser, Diversified active $1,638,477,612 10 held
4 PERCEPTIVE ADVISORS LLC Registered adviser, Diversified active $1,571,442,792 10 held
5 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $1,333,089,789 5 held
6 TCG Crossover Management, LLC Unknown, Diversified active $1,290,928,956 8 held
7 Siren, L.L.C. Unknown, Diversified active $1,077,898,378 10 held
8 Venrock Adviser, LLC Registered adviser, Concentrated $986,281,422 5 held
9 Fairmount Funds Management LLC Registered adviser, Concentrated $814,765,976 5 held
10 DEERFIELD MANAGEMENT COMPANY, L.P. Registered adviser, Diversified active $763,173,351 5 held

Fund Ownership of DFTX by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 9.33% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 2.53% 3,461,417
Index ETFs 6.81% 9,316,224
Active ETFs 0.49% 673,702
Active funds 16.16% 22,126,614
Unclassified 0.21% 289,196
All registered funds 26.20% 35,867,153
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
60
Increased
143
Decreased
98
Sold Out
68
Unchanged
55

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: -10
Institutional value: -17.0%
Shares held: +2.6%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 376
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 376 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 343 filings 334 filers Visit website Investor relations